Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
Submitted by
admin
on April 3, 2012 - 10:14am
Source:
CP Wire
News Tags:
tubulin inhibitor
AMRI
Headline:
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
Do Not Allow Advertisers to Use My Personal information
